Unknown statusInterventionalPhase 4Last updated Oct 20, 2011

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor

Overview

ClinicalTrials.gov ID: NCT01455649
Lead Sponsor: Deise de Boni Monteiro de CarvalhoOTHER
Brief Summary: The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus, with its onset after 3 months of treatment with calcineurin inhibitor.
Study Type: Interventional

Status

Overall Status: Unknown status
Start Date: Nov 2011
Primary Completion Date: Nov 2013Estimated
Completion Date: Nov 2013Estimated

Study Record Dates

First Submitted: Oct 11, 2011
First Submitted that Met QC Criteria: Oct 19, 2011
First Posted: Oct 20, 2011Estimated
Last Update Submitted that Met QC Criteria: Oct 19, 2011
Last Update Posted: Oct 20, 2011Estimated
Last Verified: Oct 2011

NCT00170820Completed

Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen

NCT02334488Completed

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

NCT00371826Completed

SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus

NCT01609673Terminated

Study of Everolimus in de Novo Renal Transplant Recipients

NCT00251004Completed

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

NCT01114529Completed

Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients